NCT00135408 - A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Malignant Melanoma

Interventions

DRUG

Ipilimumab+ Placebo

Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.

DRUG

Ipilimumab+ Budesonide

Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.

Trial Locations (10)

Unknown

Los Angeles

San Francisco

Charlotte

Seattle

Local Institution, Kitchener

Local Institution, Moncton

Local Institution, Tel Aviv

Local Institution, Forlì

Local Institution, Lima

Local Institution, Hull